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Exosomes are membranous vesicles containing various biomolecules including lncRNAs
which are involved in cellular communication and are secreted from many cells including
cancer cells. In our study, investigated the exosomal GAS5 and lincRNA-p21 lncRNA
levels in urine samples from 30 patients with prostate cancer (PCa) and 49 patients
with benign prostatic hyperplasia. Quantification of lncRNA molecules was performed by
real-time PCR. We observed a significant difference in the exosomal lincRNA-p21 levels
between PCa and BPH patients whereas the GAS5 levels did not reveal a difference. Our
data suggest that the discriminative potential of exosomal lincRNA-p21 levels may help
to improve the diagnostic prediction of the malignant state for patients with PCa.
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Introduction
Prostate cancer (PCa) is the second most common malignancy and accounts for 15% of the cancers
in men. It is the fifth leading cause of death and almost 70% of the cases occur in the developed
countries (Ferlay et al., 2015). The diagnosis of PCa is performed via histopathological evaluation
of biopsy samples which has several known disadvantages like bleeding and infection (Loeb et al.,
2013). Although use of the prostate specific antigen (PSA) as a diagnostic marker has improved the
detection and management of PCa (Lippi et al., 2009) its low specificity and lack of other predictive
parameters for the progression of the disease makes the stratification of the patients with high risk
or indolent PCa difficult (Roddam et al., 2005; Nogueira et al., 2010).
Recently, a prostate specific lncRNA, the PCaGene 3 (PCA3), has been approved as an additional test
to determine the need for biopsies in PCa. Unfortunately, negative PCA3 results in indolent cancer
carriers and high grade prostatic intraepithelial neoplasia (HGPIN;Morote et al., 2010; Auprich et al.,
2011a) renders the biomarker insufficient. The level of TMPRSS2-ERG fusion transcripts, in cells
collected from urine after digital examination, have also been evaluated together with the PCA3
levels for a more accurate diagnosis (Leyten et al., 2014). However, none of these approaches can
satisfactorily distinguish high-risk from indolent cancer. Therefore identification of new biomarkers
to correctly identify patients needing more aggressive treatment would help to prevent individuals
with localized tumors from getting unnecessary biopsies and from the side effects of overtreatment.
Exosomes are small membranous vesicles originating from the endosomal compartment which
function as messengers in intercellular communication (Simpson et al., 2008; Bang and Thum, 2012;
Gezer et al., 2014). They are secreted and released by cells and bind to the receptors on recipient
cells, thereby transferring the signal. Exosome secretion is an evolutionary conserved cellular
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mechanism dating back to Archaea but their role as cellular
messengers has been described only recently (Taylor et al., 2006;
Deatherage and Cookson, 2012). Exosomes contain proteins and
various types of RNA molecules including lncRNAs. Non-exonic
transcripts as a whole constitute the majority of non-ribosomal
RNA molecules in the cell and lincRNAs constitute a significant
portion of this fraction (Kapranov et al., 2010). Exosomes secreted
from prostate can be detected in semen (Ronquist and Brody,
1985) and urine (Pisitkun et al., 2004). In recent years it has been
shown that PCA3 and several other microRNAs are present in
exosomes isolated from PCa patients (Dijkstra et al., 2014; Huang
et al., 2015).
LincRNA-p21 and GAS5 lncRNA act as tumor suppressor
molecules in the cellularmachinery (Schneider et al., 1988;Huarte
et al., 2010). Expression of lincRNA-p21 is stimulated by the p53
tumor suppressor protein and upon transcription it suppresses
expression of the genes transcriptionally regulated by p53 by bind-
ing to the hnRNP-K complex (Huarte et al., 2010). GAS5 plays a
role in the induction of apoptosis. It suppresses several antiapop-
totic genes by binding to the glucocorticoid receptor (GR) and
hence prevents GR from binding to the glucocorticoid response
elements on the target DNA molecule (Kino et al., 2010). Recent
data indicate that lncRNA molecules may exhibit tissue- and
disease-specific expression which can provide important poten-
tial biomarkers specific to the particular cancer types (Yaman
Agaoglu et al., 2011; Gezer et al., 2014). However, it should be
noted that lncRNAmolecules are associated both with cancer and
pluripotency which can be a confounding factor (St. Laurent et al.,
2013). In this study, we aimed to evaluate the diagnostic utility
of exosomal lincRNA-p21 and GAS5 levels in individuals with
benign prostatic hyperplasia (BPH) and PCa.
Materials and Methods
Exosomal RNA Isolation
Thirty patients with PCa (median age 64  6) and 49 patients
with BPH (median age 68  9) were enrolled in the study. The
study was approved by the Ethics Committee of the Istanbul
Faculty of Medicine and informed consent was obtained from the
participants. All patients were Caucasian and the disease scores of
the patients are given inTable 1. Urine samples frompatients were
collected after digital rectal examination and were centrifuged
for 10 min at 1000 rpm in a conical tube to remove cell and
debris. Supernatant was transferred to another conical tube and
centrifuged at 2000 rpm for 10 min to remove remaining debris
and bacteria. 10 ml of cell-free urine was then transferred to a
new 15 ml tube and stored at  80°C until use. Exosomal RNA
was extracted according to the manufacturer’s protocol using the
“Urine Exosome RNA Isolation Kit” (Norgen Biotek, Thorold,
ON, Canada).
Quantification of lncRNAs
Exosomal RNA isolated from urine samples were used for cDNA
synthesis using the First Strand cDNA Synthesis kit (Thermo
Scientific, West Palm Beach, FL, USA) according to the man-
ufacturers’ instructions. The real-time amplification of lncRNA
molecules was performed using the LightCycler 480 system
TABLE 1 | Disease scores of the patients.
Benign prostatic hyperplasia patients n = 49
IPSS Score (Barry et al., 1992)
0–7 0
8–19 24
20–35 17
Unknown 8
Prostate cancer patients n = 30
Gleason score (Epstein, 2010)
6 (3+3) 19
7 (3+4) 3
7 (4+3) 4
Unknown 4
TABLE 2 | The primer sequences used in the study.
Gene Primer sequence Reference
LincRNA-p21 F 50- GGGTGGCTCACTCTTCTGGC -30
R 50- TGGCCTTGCCCGGGCTTGTC -30
Huarte et al. (2010)
GAS5 F 50-CTTCTGGGCTCAAGTGATCCT -30
R 50- TTGTGCCATGAGACTCCATCAG -30
Khalil et al. (2009)
GAPDH F 50-GCTCTCTGCTCCTCCTGTTC -30
R 50- ACGACCAAATCCGTTGACTC-30
Khalil et al. (2009)
(Roche, Germany). SYBR Green (Roche) was used as the fluores-
cent molecule. The primer sequences are shown in Table 2.
The PCR reaction included an initial “hot start” for 10 min.,
followed by 45 cycles of amplification. Each cycle consisted of
a denaturation step at 95°C for 10 s, annealing starting at 60°C
for 20 s and decreasing by 2°C every two cycles down to 55°C,
and amplification at 72°C for 30 s. For quantification of lncRNAs,
the Ct method was used. The GAPDH gene was used as the
reference. All experiments were performed twice and the mean
values were calculated.
Statistical Analyses
SPSS® ver.21.0 statistical program was used for statistical analy-
sis. Kruskal–Wallis or Mann–Whitney U tests were used when
appropriate to compare the parameters (lncRNA and PSA levels).
A p-value 0.05 was considered statistically significant.
Results
Exosomal levels of GAS5 and lncRNA-p21 lncRNAs were evalu-
ated in the urine samples of 49 patients diagnosed with BPH and
30 patients with PCa. The distribution of exosomal lncRNA levels
are shown in Figure 1. The lincRNA-p21 levels were significantly
higher in PCa than in BPH (median; 0.163 vs 0.071; p = 0.016,
AUC: 0.663). Exosomal GAS5 levels were found to be similar in
the two disease groups (median; 1.197 vs 1.235 and p = 0.127).
The data are shown in Table 3.
The PSA levels were higher in the PCa group than in the
patients with BPH (p< 0.001, median values; 7.7 and 2.16 respec-
tively). In the BPHgroup no correlationwas observed between the
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FIGURE 1 | Distribution of the exosomal GAS5 and lincRNA-p21 levels
in the disease groups. The circles and asterisks represent the values
(outliers) falling beyond the statistical distribution of the related variables
(exosomal lincRNA-p21 or GAS5).
TABLE 3 | Median values of exosomal lncRNAs and their statistical
significances.
Median BPH PCa Significance (p-value)
GAS5 1.197 1.235 0.127
LincRNA-p21 0.071 0.163 0.016
AUC value of LincRNA-p21: 0.663, CI:95%
IPSS (International Prostate Symptom Score) score and GAS5 or
lincRNA-p21 levels. Likewise, no correlation between the clinical
stage (Gleason score) and exosomal lncRNA levels was observed
in the PCa group. There was no correlation between the PSA levels
and the IPSS score in patients with BPH but a correlation was
observed between the PSA values and the Gleason score in the
PCa group (p= 0.123 and 0.049, respectively).
The sensitivity and specificity of lincRNA-p21 and lincRNA-
p21 in combination with PSA were calculated using a cut off
value of 2.5 ng/ml for PSA and 0.181 for exosomal lincRNA-p21
expression (Figure 2). The specificity for predicting PCa increased
from63 to 94%when the two parameterswere combinedwhile the
specificity did not change (Table 4).
Discussion
Our study is the first report, revealing presence of lincRNA-
p21 and GAS5 lncRNA molecules in the exosomes derived from
urine samples. Circulating GAS5 and lincRNA-p21 have been
previously detected in B-cell malignancies (Isin et al., 2014) but
exosomalGAS5 and lincRNA-p21molecules have previously been
only reported in exosomes secreted from HeLa and MCF-7 cell
lines but not in human tumors (Gezer et al., 2014). Cellular
lincRNA-p21 expression has been suggested to affect global gene
expression in different cancers by modulating mRNA transla-
tion and supressing the p53 and Wnt/b-catenin signaling path-
ways (Dimitrova et al., 2014; Wang et al., 2014). Cellular GAS5
FIGURE 2 | The ROC curve for the LincRNA-p21 and PSA combination.
TABLE 4 | Sensitivity and specificity of exosomal lncRNA-p21 and of the
lincRNA-p21/PSA combination.
LincRNA-p21 LincRNA-p21 and PSA
Sensitivity 67% 52%
Specificity 63% 94%
expression suggest a role of GAS5 in the regulation of apoptosis
in breast cancer cell lines and tumors (Pickard and Williams,
2014) and an inverse association with the mTOR expression in
PCa cell lines (Yacqub-Usman et al., 2015). In the present study,
we observed significantly higher levels of exosomal lincRNA-p21
levels in the patients with PCa.
It has been shown that one in six of the prostatectomy speci-
mens may contain indolent cancers which usually do not progress
to clinical detection during the lifetime of the patient (Epstein
et al., 1994). On the other hand, several studies suggest that more
than 50% of the cancers which are initially diagnosed as localized
tumors are actually advanced at the time of treatment (Chun et al.,
2008; Jeldres et al., 2008).
The PSA test is not sensitive enough to predict the presence,
extent and risk of recurrence of PCa (Albertsen, 2010; Zeliadt
et al., 2010; Friedrich, 2011). Therefore, there is a definite need
for non-invasive diagnostic biomarkers which can distinguish
the low- and high-risk patients in the clinical decision-making.
Even though non-invasive detection of PCA3 levels in urine after
digital rectal examination may provide some useful information
on the need of a repeated biopsy, evaluation of PCA3 also fails
to be specific (Bradley et al., 2013). Dijkstra et al. (2014) have
shown that the diagnostic performance of PCA3 in exosomes
was found to be more successful than in urine where the PCA3
score was normalized with PSA mRNA in order to achieve a
higher performance. Although their study group is quite small
the authors suggested an advantage of exosomal PCA3 evaluation
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while indicating that their data should be validated in larger clini-
cal cohorts. The discriminative capacity achieved by the exosomal
PCA3 in this study (AUC: 0.524) is lower than lincRNA-p21
(AUC: 0.663, CI: 95%) in the present study. These data indicate
that analysis of exosomal lincRNA-p21 in urine performs better
than PCA3 in detecting PCa.
Recently, there is an active controversy over decreasing the cut-
off level of PCA3 from 35 to 25 (Nakanishi et al., 2008; Auprich
et al., 2011b; de la Taille et al., 2011; Ploussard et al., 2011) which is
expected to increase its diagnostic sensitivity. A meta-analysis by
Luo et al. (2014) reported that the sensitivity of PCA3 for detecting
PCa ranges from 46.9 to 82.3% and specificity from 55 to 92%. In
our study the specificity of lincRNA-p21 for PCa was 94% when
combined with PSA.
Expression of TMPRSS2-ERG has also been analyzed in urine
samples (Leyten et al., 2014). It has been reported that combi-
nation of PCA3 and TMPRSS2-ERG expression increased the
sensitivity of detecting PCa. However, the biomarker pair still
failed to detect indolent tumors with a Gleason score of7.
A new study investigating exosomal microRNA molecules
derived from plasma samples in 29 castration resistant PCa
(CRPCa) patients reported two significant miRNA molecules
(miR-1290 and miR-375) which were later evaluated in 100
patients with CRPCa, as a prognostic marker significantly associ-
ated with poor prognosis, needing prospective validation (Huang
et al., 2015).
In absence of reliable markers for detection and classification
of PCa urinary exosomal lncRNAs may can provide an alterna-
tive, and non-invasive source of biomarkers. The stability and
longevity of the RNAmolecules is ideal for non-invasive diagnosis
and characterization of the tumors. Our study for the first time
demonstrates that detection of exosomal lncRNAs in urine may
act as suitable biomarkers with potential utility of therapeutic
implications. LincRNA-p21 provides a promising marker with
therapeutic potential for the detection and stratification of PCa.
Further studies with larger patient groups are needed to vali-
date the therapeutic utility of exosomal lincRNA-p21 levels in
urine.
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